GDF15 and atrial fibrillation: In a sub-analysis from the ARISTOTLE trial, including more than 18,000 patients with atrial fibrillation randomized to either apixaban or warfarin, GDF-15 predicted major bleeding events, stroke or systemic embolism and mortality, independently of NT-proBNP or hs-cTnI [90].